Galderma Group AG (SWX: GALD)
Health Care · Pharmaceuticals · CH
CHF172.70
+0.64% today · +25.2% 1Y
Galderma Group AG (SWX: GALD) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $49.84B and employs 7,676 people.
Over the last twelve months the share price has gained 25.2%, trading between 130.20 and 188.25.
Tweenvest scores Galderma Group AG across four factors: quality 64/100, value 48/100, dividend 2/100. Its strongest factor is quality.
GALD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $49.84B
- Revenue (TTM)
- $5.92B
- P/E
- 58.15
- EPS
- 3.65
- Dividend yield
- 0.21%
- Beta (5Y)
- -0.10
- 52-week high
- CHF188.25
- 52-week low
- CHF130.20
- Avg volume (3M)
- —
- Shares outstanding
- 233.19M
- Employees
- 7,676
- Next earnings
- —
About Galderma Group AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
- ISIN
- CH1335392721
- Founded
- 1981
- Listed since
- Mar 22, 2024
- Exchange
- SIX Swiss Exchange
- Currency
- CHF
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,192.07 | -3.37% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $270.44 | -0.99% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.50 | -1.89% |
| Roche Holding AGSWX: ROP | $371.62B | CHF369.90 | -1.04% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.60 | -1.73% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.